Clinical trial
Safety and Pharmacokinetics of Recombinant Factor XIII in Patients With…
NCT00056589 · Novo Nordisk A/S, Industry · Completed
Key facts
| NCT number | NCT00056589 |
|---|---|
| Title | Safety and Pharmacokinetics of Recombinant Factor XIII in Patients With Congenital Factor Xlll Deficiency |
| Official title | A Phase 1 Escalating Dose Study of the Safety and Pharmacokinetics of Recombinant Factor XIII in Patients With Congenital Factor XIII Deficiency |
| Lead sponsor | Novo Nordisk A/S, Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Congenital Bleeding Disorder, Congenital FXIII Deficiency |
| Intervention type | Drug |
| Interventions | catridecacog |
| Enrollment | 11 |
| Start date | Mar 1, 2003 |
| Primary completion | Oct 1, 2003 |
| Completion | Oct 1, 2003 |
| First posted | Mar 20, 2003 |
| Last update posted | Jan 11, 2017 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: